Literature DB >> 22672868

Wolcott-Rallison syndrome due to a novel mutation (R491X) in EIF2AK3 gene.

Ercan Mihci1, Doğa Türkkahraman, Sian Ellard, Sema Akçurin, Iffet Bircan.   

Abstract

Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disorder characterized by early-onset diabetes, spondyloepiphyseal dysplasia, tendency to skeletal fractures secondary to osteopenia, and growth retardation. Mutations in the eukaryotic translation initiation factor 2α kinase (EIF2AK3) gene are responsible for this disorder. Here, we describe a boy with neonatal diabetes, diagnosed at 2 months of age, who developed severe growth retardation and a skeletal fracture during the follow-up period. The patient's skeletal X-ray revealed findings of skeletal dysplasia. A clinical diagnosis of WRS was confirmed by the identification of a novel homozygous nonsense mutation (R491X) in exon 9 of the EIF2AK3 gene. The aim of this report is to raise the awareness for Wolcott-Rallison syndrome in cases presenting with isolated neonatal diabetes. This patient demonstrates that the other findings of this syndrome might be obscured by a diagnosis of isolated neonatal diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672868      PMCID: PMC3386768          DOI: 10.4274/jcrpe.619

Source DB:  PubMed          Journal:  J Clin Res Pediatr Endocrinol


INTRODUCTION

Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disorder characterized by early-onset diabetes mellitus, skeletal dysplasia (especially multiple epiphyseal dysplasia), osteoporosis and growth retardation (1). Other occasional findings of WRS include central hypothyroidism, hepatic dysfunction, renal insufficiency, central nervous system abnormalities, cardiorespiratory defects, and hypothalamic-pituitary dysfunction (2,3,4,5,6,7). To date, less than 100 cases have been described (8). Mutations in the eukaryotic translation initiation factor 2α kinase (EIF2AK3) gene are responsible for this disorder (9). The EIF2AK3 gene regulates protein synthesis by phosphorylating the α-subunit of the eukaryotic initiation factor-2 (eIF2) in the endoplasmic reticulum and is specifically required in the insulin-secreting β-cells during fetal life and early neonatal period (10). Here, we report a novel nonsense mutation (R491X) in the EIF2AK3 gene in a patient with WRS.

CASE REPORT

The male proband is an infant of Turkish ancestry who was born at 39 weeks gestation by caesarean section with a birth weight of 2300g (<3rd percentile, small for gestational age). His parents were second-degree cousins. Family history was unremarkable. At 2 months of age, the patient had been diagnosed to have neonatal diabetes. Diabetes-associated auto-antibodies were negative. He was discharged with a regimen of NPH and regular insulin injections twice a day.At age 5.5 years, the patient was still on insulin therapy(0.9 U/kg/day). His HbA1c level was 7.7%. Mental-motor development was normal. His height percentile was below 3rd percentile (height SD score: -2.6) and his growth velocity was low (3.6 cm/year). Thyroid function tests were normal, and anti-gliadin IgA was negative for celiac disease. Bone age was retarded by 1.5 years. He had proportionate short stature, and had no sign of skeletal abnormalities.At age 7 years, the patient was admitted to our hospital with a right-sided femur fracture following a simple trauma. X-ray films showed findings consistent with skeletal dysplasia. Additionally, he had a protuberant abdomen, lumbar lordosis and extension limitation in all joints (Figure 1). Height was severely retarded (102.6 cm, height SD score: -3.6). Growth velocity was 2 cm per year despite his better metabolic control. X-rays revealed beaking of both thoracic and lumbar vertebrae, spina bifida at L5 vertebrae and generalized epiphyseal-metaphyseal dysplasia (Figure 2). Dual-energy X-ray absorptiometry (DEXA) showed osteopenia according to height-age (L2-4 Z-score: -1.6), and abdominal ultrasonography revealed hypoplasia of the pancreas (severely atrophic). Cerebellar atrophy was detected on cranial magnetic resonance imaging.
Figure 1

Photograph of the patient demonstrating posture

Figure 2

X-ray films demonstrating beaking of both thoracic and lumbarvertebrae, spina bifida at L5 vertebrae, generalized epiphysealmetaphysealdysplasia and osteopenia of the skeletal system

These findings led us to re-evaluate the diagnosis of this patient. WRS was considered as the most plausible diagnosis because of coexistence of neonatal diabetes and skeletal abnormalities. At this time, the patient was found to have elevated liver enzyme values. However, these values decreased and returned to normal within a week and were linked to an episode of viral infection. Genomic DNA was extracted from peripheral leukocytes using standard procedures. The coding exons and the intron-exon boundaries of the EIF2AK3 gene were PCR-amplified; primers and conditions are available upon request. Sequence-specific primers for each amplicon were tagged with 5' M13 tails to allow sequencing to be performed with a "universal" M13 primer. Single-strand sequencing was performed using standard methods on an ABI 3730 (Applied Biosystems, Warrington, UK). Sequences were compared to the published template (accession number AF110146.1) using Mutation Surveyor v3.24 (SoftGenetics, PA, USA). Any changes in the sequence were checked against published polymorphisms and mutations and for conservation across species. Sequence variants were tested for their presence in family members whenever a DNA sample was available.Sequencing analysis has shown that the patient is homozygous for a novel nonsense mutation, R491X (c.1471C>T; p.Arg491X), in exon 9 of the EIF2AK3 gene. Both his mother and father were heterozygous carriers for this mutation (Figure 3).
Figure 3

Identification of the mutation in the EIF2AK3 gene. Sequencesshow normal DNA, heterozygous parents, and the findings in the patient

DISCUSSION

Permanent neonatal diabetes mellitus (PNDM) is a very rare clinical condition defined as diabetes diagnosed within the first 6 months of life that does not remit. The estimated incidence of PNDM is 1 in 260 000 and it is most commonly caused by the mutations in the KCNJ11, ABCC8 and INS genes (11,12,13,14). The mutations in the gene encoding EIF2AK3 are responsible for WRS. Our patient was found to be homozygous for a novel nonsense mutation (R491X) in exon 9 of the EIF2AK3 gene. His mother and father, who were second cousins, were confirmed as heterozygous carriers. A recent study has shown that WRS is the most common cause of PNDM in consanguineous pedigrees (8). In addition to testing patients with a definite clinical diagnosis, these authors recommend that EIF2AK3 mutations should be sought in patients with isolated neonatal diabetes diagnosed after 3 weeks of age from known consanguineous families, isolated populations, or countries where inbreeding is common. In the literature, the major skeletal abnormalities of WRS are listed as osteoporosis, osteopenia, thoracolumbar kyphosis and bowing of the femora (6). In our patient, osteopenia, beaked thoracic and lumbar vertebrae, a spina bifida at L5 vertebrae and generalized epiphyseal-metaphyseal dysplasia were all present. Various central nervous system anomalies including cerebellar cortical dysplasia, cerebral atrophy and pachygyria have been described in patients with WRS (6,15,16). Our patient was also found to have cerebellar hypoplasia, which is one of the very rare central nervous system abnormalities of WRS. Severe pancreatic hypoplasia with prominent islets of Langerhans, an important finding of WRS, was present in our patient as well. Notably, in our patient, even though we regulated his blood glucose levels with intensive insulin therapy, and excluded other possible pathologies, growth velocity remained very low. Low growth velocity in such patients might be an initial finding for suspecting WRS in patients presenting with subtle skeletal abnormalities. In conclusion, the findings in this patient indicate that WRS can present initially as neonatal diabetes mellitus, obscuring the other findings of this syndrome. On the other hand, especially in consanguineous families, even when there is no evidence of skeletal abnormalities, the diagnosis of WRS should be kept in mind in infants/children with growth retardation.
  15 in total

1.  EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome.

Authors:  M Delépine; M Nicolino; T Barrett; M Golamaully; G M Lathrop; C Julier
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

2.  Microcephaly and simplified gyral pattern of the brain associated with early onset insulin-dependent diabetes mellitus.

Authors:  M C Y de Wit; I F M de Coo; C Julier; M Delépine; M H Lequin; I van de Laar; B J Sibbles; G J Bruining; G M S Mancini
Journal:  Neurogenetics       Date:  2006-09-14       Impact factor: 2.660

3.  Wolcott-Rallison syndrome: clinical, radiological and histological findings in a Saudi child.

Authors:  B Bin-Abbas; S Shabib; B Hainau; A Al-Ashwal
Journal:  Ann Saudi Med       Date:  2001 Jan-Mar       Impact factor: 1.526

4.  Autopsy findings in the Wolcott-Rallison syndrome.

Authors:  C M Thornton; D J Carson; F J Stewart
Journal:  Pediatr Pathol Lab Med       Date:  1997 May-Jun

5.  Infancy-onset diabetes mellitus and multiple epiphyseal dysplasia.

Authors:  C D Wolcott; M L Rallison
Journal:  J Pediatr       Date:  1972-02       Impact factor: 4.406

Review 6.  Wolcott-Rallison syndrome: a clinical and genetic study of three children, novel mutation in EIF2AK3 and a review of the literature.

Authors:  S Iyer; M Korada; L Rainbow; J Kirk; R M Brown; N Shaw; T G Barrett
Journal:  Acta Paediatr       Date:  2004-09       Impact factor: 2.299

7.  Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families.

Authors:  Oscar Rubio-Cabezas; Ann-Marie Patch; Jayne A L Minton; Sarah E Flanagan; Emma L Edghill; Khalid Hussain; Amina Balafrej; Asma Deeb; Charles R Buchanan; Ian G Jefferson; Angham Mutair; Andrew T Hattersley; Sian Ellard
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

8.  Wolcott-Rallison syndrome in two siblings with isolated central hypothyroidism.

Authors:  Bassam Bin-Abbas; Abdulmohsen Al-Mulhim; Abdullah Al-Ashwal
Journal:  Am J Med Genet       Date:  2002-08-01

9.  Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.

Authors:  Andrey P Babenko; Michel Polak; Hélène Cavé; Kanetee Busiah; Paul Czernichow; Raphael Scharfmann; Joseph Bryan; Lydia Aguilar-Bryan; Martine Vaxillaire; Philippe Froguel
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

10.  Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births.

Authors:  A S Slingerland; B M Shields; S E Flanagan; G J Bruining; K Noordam; A Gach; W Mlynarski; M T Malecki; A T Hattersley; S Ellard
Journal:  Diabetologia       Date:  2009-06-05       Impact factor: 10.122

View more
  4 in total

Review 1.  Frequency and spectrum of Wolcott-Rallison syndrome in Saudi Arabia: a systematic review.

Authors:  Abdelhadi M Habeb
Journal:  Libyan J Med       Date:  2013-06-10       Impact factor: 1.743

2.  Recurrent Hepatitis in Two Iranian Children: A Novel (Q166R) Mutation in EIF2AK3 Leading to Wolcott-Rallison Syndrome.

Authors:  Babak Behnam; Marjan Shakiba; Ali Ahani; Maryam Razzaghy Azar
Journal:  Hepat Mon       Date:  2013-06-09       Impact factor: 0.660

3.  Whole-genome sequence analysis reveals differences in population management and selection of European low-input pig breeds.

Authors:  Juan Manuel Herrero-Medrano; Hendrik-Jan Megens; Martien A M Groenen; Mirte Bosse; Miguel Pérez-Enciso; Richard P M A Crooijmans
Journal:  BMC Genomics       Date:  2014-07-16       Impact factor: 3.969

4.  Wolcott-Rallison Syndrome with Novel EIF2AK3 Gene Mutation.

Authors:  Fatih Gürbüz; Bilgin Yüksel; Ali Kemal Topaloğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-06-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.